 | • レポートコード：MRC2-11QY00944 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、119ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は皮膚筋炎治療薬のグローバル市場について調査・分析したレポートです。種類別（アバタセプト、バリシチニブ、ダラザチド、免疫グロブリン、IMO-8400、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別皮膚筋炎治療薬の競争状況、市場シェア ・世界の皮膚筋炎治療薬市場：種類別市場規模 2015年-2020年（アバタセプト、バリシチニブ、ダラザチド、免疫グロブリン、IMO-8400、その他） ・世界の皮膚筋炎治療薬市場：種類別市場規模予測 2021年-2026年（アバタセプト、バリシチニブ、ダラザチド、免疫グロブリン、IMO-8400、その他） ・世界の皮膚筋炎治療薬市場：用途別市場規模 2015年-2020年（病院、診療所、その他） ・世界の皮膚筋炎治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他） ・北米の皮膚筋炎治療薬市場分析：米国、カナダ ・ヨーロッパの皮膚筋炎治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの皮膚筋炎治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の皮膚筋炎治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの皮膚筋炎治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：MedImmune LLC、Neovacs SA、Novartis AG、Octapharma AG、Pfizer Inc、Eli Lilly and Company、F. Hoffmann-La Roche Ltd、Hope Pharmaceuticals Inc、Idera Pharmaceuticals Inc、KPI Therapeutics Inc、Marathon Pharmaceuticals LLC ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Dermatomyositis Drug Market
The global Dermatomyositis Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Dermatomyositis Drug Scope and Market Size
Dermatomyositis Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Dermatomyositis Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Dermatomyositis Drug market is segmented into
Abatacept
Baricitinib
Dalazatide
Immune Globulin
IMO-8400
Others
Segment by Application, the Dermatomyositis Drug market is segmented into
Hospital
Clinic
Others
Regional and Country-level Analysis
The Dermatomyositis Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Dermatomyositis Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Dermatomyositis Drug Market Share Analysis
Dermatomyositis Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Dermatomyositis Drug business, the date to enter into the Dermatomyositis Drug market, Dermatomyositis Drug product introduction, recent developments, etc.
The major vendors covered:
MedImmune LLC
Neovacs SA
Novartis AG
Octapharma AG
Pfizer Inc
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Hope Pharmaceuticals Inc
Idera Pharmaceuticals Inc
KPI Therapeutics Inc
Marathon Pharmaceuticals LLC
1 Study Coverage
1.1 Dermatomyositis Drug Product Introduction
1.2 Market Segments
1.3 Key Dermatomyositis Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Dermatomyositis Drug Market Size Growth Rate by Type
1.4.2 Abatacept
1.4.3 Baricitinib
1.4.4 Dalazatide
1.4.5 Immune Globulin
1.4.6 IMO-8400
1.4.7 Others
1.5 Market by Application
1.5.1 Global Dermatomyositis Drug Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Dermatomyositis Drug Market Size, Estimates and Forecasts
2.1.1 Global Dermatomyositis Drug Revenue 2015-2026
2.1.2 Global Dermatomyositis Drug Sales 2015-2026
2.2 Global Dermatomyositis Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Dermatomyositis Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Dermatomyositis Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Dermatomyositis Drug Competitor Landscape by Players
3.1 Dermatomyositis Drug Sales by Manufacturers
3.1.1 Dermatomyositis Drug Sales by Manufacturers (2015-2020)
3.1.2 Dermatomyositis Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Dermatomyositis Drug Revenue by Manufacturers
3.2.1 Dermatomyositis Drug Revenue by Manufacturers (2015-2020)
3.2.2 Dermatomyositis Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Dermatomyositis Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Dermatomyositis Drug Revenue in 2019
3.2.5 Global Dermatomyositis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Dermatomyositis Drug Price by Manufacturers
3.4 Dermatomyositis Drug Manufacturing Base Distribution, Product Types
3.4.1 Dermatomyositis Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Dermatomyositis Drug Product Type
3.4.3 Date of International Manufacturers Enter into Dermatomyositis Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Dermatomyositis Drug Market Size by Type (2015-2020)
4.1.1 Global Dermatomyositis Drug Sales by Type (2015-2020)
4.1.2 Global Dermatomyositis Drug Revenue by Type (2015-2020)
4.1.3 Dermatomyositis Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Dermatomyositis Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Dermatomyositis Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Dermatomyositis Drug Revenue Forecast by Type (2021-2026)
4.2.3 Dermatomyositis Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Dermatomyositis Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Dermatomyositis Drug Market Size by Application (2015-2020)
5.1.1 Global Dermatomyositis Drug Sales by Application (2015-2020)
5.1.2 Global Dermatomyositis Drug Revenue by Application (2015-2020)
5.1.3 Dermatomyositis Drug Price by Application (2015-2020)
5.2 Dermatomyositis Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Dermatomyositis Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Dermatomyositis Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Dermatomyositis Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America Dermatomyositis Drug by Country
6.1.1 North America Dermatomyositis Drug Sales by Country
6.1.2 North America Dermatomyositis Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Dermatomyositis Drug Market Facts & Figures by Type
6.3 North America Dermatomyositis Drug Market Facts & Figures by Application
7 Europe
7.1 Europe Dermatomyositis Drug by Country
7.1.1 Europe Dermatomyositis Drug Sales by Country
7.1.2 Europe Dermatomyositis Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Dermatomyositis Drug Market Facts & Figures by Type
7.3 Europe Dermatomyositis Drug Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Dermatomyositis Drug by Region
8.1.1 Asia Pacific Dermatomyositis Drug Sales by Region
8.1.2 Asia Pacific Dermatomyositis Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Dermatomyositis Drug Market Facts & Figures by Type
8.3 Asia Pacific Dermatomyositis Drug Market Facts & Figures by Application
9 Latin America
9.1 Latin America Dermatomyositis Drug by Country
9.1.1 Latin America Dermatomyositis Drug Sales by Country
9.1.2 Latin America Dermatomyositis Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Dermatomyositis Drug Market Facts & Figures by Type
9.3 Central & South America Dermatomyositis Drug Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Dermatomyositis Drug by Country
10.1.1 Middle East and Africa Dermatomyositis Drug Sales by Country
10.1.2 Middle East and Africa Dermatomyositis Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Dermatomyositis Drug Market Facts & Figures by Type
10.3 Middle East and Africa Dermatomyositis Drug Market Facts & Figures by Application
11 Company Profiles
11.1 MedImmune LLC
11.1.1 MedImmune LLC Corporation Information
11.1.2 MedImmune LLC Description and Business Overview
11.1.3 MedImmune LLC Sales, Revenue and Gross Margin (2015-2020)
11.1.4 MedImmune LLC Dermatomyositis Drug Products Offered
11.1.5 MedImmune LLC Related Developments
11.2 Neovacs SA
11.2.1 Neovacs SA Corporation Information
11.2.2 Neovacs SA Description and Business Overview
11.2.3 Neovacs SA Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Neovacs SA Dermatomyositis Drug Products Offered
11.2.5 Neovacs SA Related Developments
11.3 Novartis AG
11.3.1 Novartis AG Corporation Information
11.3.2 Novartis AG Description and Business Overview
11.3.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Novartis AG Dermatomyositis Drug Products Offered
11.3.5 Novartis AG Related Developments
11.4 Octapharma AG
11.4.1 Octapharma AG Corporation Information
11.4.2 Octapharma AG Description and Business Overview
11.4.3 Octapharma AG Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Octapharma AG Dermatomyositis Drug Products Offered
11.4.5 Octapharma AG Related Developments
11.5 Pfizer Inc
11.5.1 Pfizer Inc Corporation Information
11.5.2 Pfizer Inc Description and Business Overview
11.5.3 Pfizer Inc Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Pfizer Inc Dermatomyositis Drug Products Offered
11.5.5 Pfizer Inc Related Developments
11.6 Eli Lilly and Company
11.6.1 Eli Lilly and Company Corporation Information
11.6.2 Eli Lilly and Company Description and Business Overview
11.6.3 Eli Lilly and Company Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Eli Lilly and Company Dermatomyositis Drug Products Offered
11.6.5 Eli Lilly and Company Related Developments
11.7 F. Hoffmann-La Roche Ltd
11.7.1 F. Hoffmann-La Roche Ltd Corporation Information
11.7.2 F. Hoffmann-La Roche Ltd Description and Business Overview
11.7.3 F. Hoffmann-La Roche Ltd Sales, Revenue and Gross Margin (2015-2020)
11.7.4 F. Hoffmann-La Roche Ltd Dermatomyositis Drug Products Offered
11.7.5 F. Hoffmann-La Roche Ltd Related Developments
11.8 Hope Pharmaceuticals Inc
11.8.1 Hope Pharmaceuticals Inc Corporation Information
11.8.2 Hope Pharmaceuticals Inc Description and Business Overview
11.8.3 Hope Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Hope Pharmaceuticals Inc Dermatomyositis Drug Products Offered
11.8.5 Hope Pharmaceuticals Inc Related Developments
11.9 Idera Pharmaceuticals Inc
11.9.1 Idera Pharmaceuticals Inc Corporation Information
11.9.2 Idera Pharmaceuticals Inc Description and Business Overview
11.9.3 Idera Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Idera Pharmaceuticals Inc Dermatomyositis Drug Products Offered
11.9.5 Idera Pharmaceuticals Inc Related Developments
11.10 KPI Therapeutics Inc
11.10.1 KPI Therapeutics Inc Corporation Information
11.10.2 KPI Therapeutics Inc Description and Business Overview
11.10.3 KPI Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.10.4 KPI Therapeutics Inc Dermatomyositis Drug Products Offered
11.10.5 KPI Therapeutics Inc Related Developments
11.1 MedImmune LLC
11.1.1 MedImmune LLC Corporation Information
11.1.2 MedImmune LLC Description and Business Overview
11.1.3 MedImmune LLC Sales, Revenue and Gross Margin (2015-2020)
11.1.4 MedImmune LLC Dermatomyositis Drug Products Offered
11.1.5 MedImmune LLC Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Dermatomyositis Drug Market Estimates and Projections by Region
12.1.1 Global Dermatomyositis Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Dermatomyositis Drug Revenue Forecast by Regions 2021-2026
12.2 North America Dermatomyositis Drug Market Size Forecast (2021-2026)
12.2.1 North America: Dermatomyositis Drug Sales Forecast (2021-2026)
12.2.2 North America: Dermatomyositis Drug Revenue Forecast (2021-2026)
12.2.3 North America: Dermatomyositis Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Dermatomyositis Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Dermatomyositis Drug Sales Forecast (2021-2026)
12.3.2 Europe: Dermatomyositis Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Dermatomyositis Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Dermatomyositis Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Dermatomyositis Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Dermatomyositis Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Dermatomyositis Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Dermatomyositis Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Dermatomyositis Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Dermatomyositis Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Dermatomyositis Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Dermatomyositis Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Dermatomyositis Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Dermatomyositis Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Dermatomyositis Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Dermatomyositis Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Dermatomyositis Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Dermatomyositis Drug Market Segments
Table 2. Ranking of Global Top Dermatomyositis Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Dermatomyositis Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Abatacept
Table 5. Major Manufacturers of Baricitinib
Table 6. Major Manufacturers of Dalazatide
Table 7. Major Manufacturers of Immune Globulin
Table 8. Major Manufacturers of IMO-8400
Table 9. Major Manufacturers of Others
Table 10. Global Dermatomyositis Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 11. Global Dermatomyositis Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 12. Global Dermatomyositis Drug Sales by Regions 2015-2020 (K Pcs)
Table 13. Global Dermatomyositis Drug Sales Market Share by Regions (2015-2020)
Table 14. Global Dermatomyositis Drug Revenue by Regions 2015-2020 (US$ Million)
Table 15. Global Dermatomyositis Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 16. Global Dermatomyositis Drug Sales Share by Manufacturers (2015-2020)
Table 17. Global Dermatomyositis Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 18. Global Dermatomyositis Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Dermatomyositis Drug as of 2019)
Table 19. Dermatomyositis Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 20. Dermatomyositis Drug Revenue Share by Manufacturers (2015-2020)
Table 21. Key Manufacturers Dermatomyositis Drug Price (2015-2020) (USD/Pcs)
Table 22. Dermatomyositis Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Dermatomyositis Drug Product Type
Table 24. Date of International Manufacturers Enter into Dermatomyositis Drug Market
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Global Dermatomyositis Drug Sales by Type (2015-2020) (K Pcs)
Table 27. Global Dermatomyositis Drug Sales Share by Type (2015-2020)
Table 28. Global Dermatomyositis Drug Revenue by Type (2015-2020) (US$ Million)
Table 29. Global Dermatomyositis Drug Revenue Share by Type (2015-2020)
Table 30. Dermatomyositis Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 31. Global Dermatomyositis Drug Sales by Application (2015-2020) (K Pcs)
Table 32. Global Dermatomyositis Drug Sales Share by Application (2015-2020)
Table 33. North America Dermatomyositis Drug Sales by Country (2015-2020) (K Pcs)
Table 34. North America Dermatomyositis Drug Sales Market Share by Country (2015-2020)
Table 35. North America Dermatomyositis Drug Revenue by Country (2015-2020) (US$ Million)
Table 36. North America Dermatomyositis Drug Revenue Market Share by Country (2015-2020)
Table 37. North America Dermatomyositis Drug Sales by Type (2015-2020) (K Pcs)
Table 38. North America Dermatomyositis Drug Sales Market Share by Type (2015-2020)
Table 39. North America Dermatomyositis Drug Sales by Application (2015-2020) (K Pcs)
Table 40. North America Dermatomyositis Drug Sales Market Share by Application (2015-2020)
Table 41. Europe Dermatomyositis Drug Sales by Country (2015-2020) (K Pcs)
Table 42. Europe Dermatomyositis Drug Sales Market Share by Country (2015-2020)
Table 43. Europe Dermatomyositis Drug Revenue by Country (2015-2020) (US$ Million)
Table 44. Europe Dermatomyositis Drug Revenue Market Share by Country (2015-2020)
Table 45. Europe Dermatomyositis Drug Sales by Type (2015-2020) (K Pcs)
Table 46. Europe Dermatomyositis Drug Sales Market Share by Type (2015-2020)
Table 47. Europe Dermatomyositis Drug Sales by Application (2015-2020) (K Pcs)
Table 48. Europe Dermatomyositis Drug Sales Market Share by Application (2015-2020)
Table 49. Asia Pacific Dermatomyositis Drug Sales by Region (2015-2020) (K Pcs)
Table 50. Asia Pacific Dermatomyositis Drug Sales Market Share by Region (2015-2020)
Table 51. Asia Pacific Dermatomyositis Drug Revenue by Region (2015-2020) (US$ Million)
Table 52. Asia Pacific Dermatomyositis Drug Revenue Market Share by Region (2015-2020)
Table 53. Asia Pacific Dermatomyositis Drug Sales by Type (2015-2020) (K Pcs)
Table 54. Asia Pacific Dermatomyositis Drug Sales Market Share by Type (2015-2020)
Table 55. Asia Pacific Dermatomyositis Drug Sales by Application (2015-2020) (K Pcs)
Table 56. Asia Pacific Dermatomyositis Drug Sales Market Share by Application (2015-2020)
Table 57. Latin America Dermatomyositis Drug Sales by Country (2015-2020) (K Pcs)
Table 58. Latin America Dermatomyositis Drug Sales Market Share by Country (2015-2020)
Table 59. Latin Americaa Dermatomyositis Drug Revenue by Country (2015-2020) (US$ Million)
Table 60. Latin America Dermatomyositis Drug Revenue Market Share by Country (2015-2020)
Table 61. Latin America Dermatomyositis Drug Sales by Type (2015-2020) (K Pcs)
Table 62. Latin America Dermatomyositis Drug Sales Market Share by Type (2015-2020)
Table 63. Latin America Dermatomyositis Drug Sales by Application (2015-2020) (K Pcs)
Table 64. Latin America Dermatomyositis Drug Sales Market Share by Application (2015-2020)
Table 65. Middle East and Africa Dermatomyositis Drug Sales by Country (2015-2020) (K Pcs)
Table 66. Middle East and Africa Dermatomyositis Drug Sales Market Share by Country (2015-2020)
Table 67. Middle East and Africa Dermatomyositis Drug Revenue by Country (2015-2020) (US$ Million)
Table 68. Middle East and Africa Dermatomyositis Drug Revenue Market Share by Country (2015-2020)
Table 69. Middle East and Africa Dermatomyositis Drug Sales by Type (2015-2020) (K Pcs)
Table 70. Middle East and Africa Dermatomyositis Drug Sales Market Share by Type (2015-2020)
Table 71. Middle East and Africa Dermatomyositis Drug Sales by Application (2015-2020) (K Pcs)
Table 72. Middle East and Africa Dermatomyositis Drug Sales Market Share by Application (2015-2020)
Table 73. MedImmune LLC Corporation Information
Table 74. MedImmune LLC Description and Major Businesses
Table 75. MedImmune LLC Dermatomyositis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 76. MedImmune LLC Product
Table 77. MedImmune LLC Recent Development
Table 78. Neovacs SA Corporation Information
Table 79. Neovacs SA Description and Major Businesses
Table 80. Neovacs SA Dermatomyositis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 81. Neovacs SA Product
Table 82. Neovacs SA Recent Development
Table 83. Novartis AG Corporation Information
Table 84. Novartis AG Description and Major Businesses
Table 85. Novartis AG Dermatomyositis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 86. Novartis AG Product
Table 87. Novartis AG Recent Development
Table 88. Octapharma AG Corporation Information
Table 89. Octapharma AG Description and Major Businesses
Table 90. Octapharma AG Dermatomyositis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 91. Octapharma AG Product
Table 92. Octapharma AG Recent Development
Table 93. Pfizer Inc Corporation Information
Table 94. Pfizer Inc Description and Major Businesses
Table 95. Pfizer Inc Dermatomyositis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 96. Pfizer Inc Product
Table 97. Pfizer Inc Recent Development
Table 98. Eli Lilly and Company Corporation Information
Table 99. Eli Lilly and Company Description and Major Businesses
Table 100. Eli Lilly and Company Dermatomyositis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 101. Eli Lilly and Company Product
Table 102. Eli Lilly and Company Recent Development
Table 103. F. Hoffmann-La Roche Ltd Corporation Information
Table 104. F. Hoffmann-La Roche Ltd Description and Major Businesses
Table 105. F. Hoffmann-La Roche Ltd Dermatomyositis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 106. F. Hoffmann-La Roche Ltd Product
Table 107. F. Hoffmann-La Roche Ltd Recent Development
Table 108. Hope Pharmaceuticals Inc Corporation Information
Table 109. Hope Pharmaceuticals Inc Description and Major Businesses
Table 110. Hope Pharmaceuticals Inc Dermatomyositis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 111. Hope Pharmaceuticals Inc Product
Table 112. Hope Pharmaceuticals Inc Recent Development
Table 113. Idera Pharmaceuticals Inc Corporation Information
Table 114. Idera Pharmaceuticals Inc Description and Major Businesses
Table 115. Idera Pharmaceuticals Inc Dermatomyositis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 116. Idera Pharmaceuticals Inc Product
Table 117. Idera Pharmaceuticals Inc Recent Development
Table 118. KPI Therapeutics Inc Corporation Information
Table 119. KPI Therapeutics Inc Description and Major Businesses
Table 120. KPI Therapeutics Inc Dermatomyositis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 121. KPI Therapeutics Inc Product
Table 122. KPI Therapeutics Inc Recent Development
Table 123. Marathon Pharmaceuticals LLC Corporation Information
Table 124. Marathon Pharmaceuticals LLC Description and Major Businesses
Table 125. Marathon Pharmaceuticals LLC Dermatomyositis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 126. Marathon Pharmaceuticals LLC Product
Table 127. Marathon Pharmaceuticals LLC Recent Development
Table 128. Global Dermatomyositis Drug Sales Forecast by Regions (2021-2026) (K Pcs)
Table 129. Global Dermatomyositis Drug Sales Market Share Forecast by Regions (2021-2026)
Table 130. Global Dermatomyositis Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 131. Global Dermatomyositis Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 132. North America: Dermatomyositis Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 133. North America: Dermatomyositis Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 134. Europe: Dermatomyositis Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 135. Europe: Dermatomyositis Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 136. Asia Pacific: Dermatomyositis Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 137. Asia Pacific: Dermatomyositis Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 138. Latin America: Dermatomyositis Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 139. Latin America: Dermatomyositis Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 140. Middle East and Africa: Dermatomyositis Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 141. Middle East and Africa: Dermatomyositis Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 142. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 143. Key Challenges
Table 144. Market Risks
Table 145. Main Points Interviewed from Key Dermatomyositis Drug Players
Table 146. Dermatomyositis Drug Customers List
Table 147. Dermatomyositis Drug Distributors List
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Dermatomyositis Drug Product Picture
Figure 2. Global Dermatomyositis Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Abatacept Product Picture
Figure 4. Baricitinib Product Picture
Figure 5. Dalazatide Product Picture
Figure 6. Immune Globulin Product Picture
Figure 7. IMO-8400 Product Picture
Figure 8. Others Product Picture
Figure 9. Global Dermatomyositis Drug Sales Market Share by Application in 2020 & 2026
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Dermatomyositis Drug Report Years Considered
Figure 14. Global Dermatomyositis Drug Market Size 2015-2026 (US$ Million)
Figure 15. Global Dermatomyositis Drug Sales 2015-2026 (K Pcs)
Figure 16. Global Dermatomyositis Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 17. Global Dermatomyositis Drug Sales Market Share by Region (2015-2020)
Figure 18. Global Dermatomyositis Drug Sales Market Share by Region in 2019
Figure 19. Global Dermatomyositis Drug Revenue Market Share by Region (2015-2020)
Figure 20. Global Dermatomyositis Drug Revenue Market Share by Region in 2019
Figure 21. Global Dermatomyositis Drug Sales Share by Manufacturer in 2019
Figure 22. The Top 10 and 5 Players Market Share by Dermatomyositis Drug Revenue in 2019
Figure 23. Dermatomyositis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 24. Global Dermatomyositis Drug Sales Market Share by Type (2015-2020)
Figure 25. Global Dermatomyositis Drug Sales Market Share by Type in 2019
Figure 26. Global Dermatomyositis Drug Revenue Market Share by Type (2015-2020)
Figure 27. Global Dermatomyositis Drug Revenue Market Share by Type in 2019
Figure 28. Global Dermatomyositis Drug Market Share by Price Range (2015-2020)
Figure 29. Global Dermatomyositis Drug Sales Market Share by Application (2015-2020)
Figure 30. Global Dermatomyositis Drug Sales Market Share by Application in 2019
Figure 31. Global Dermatomyositis Drug Revenue Market Share by Application (2015-2020)
Figure 32. Global Dermatomyositis Drug Revenue Market Share by Application in 2019
Figure 33. North America Dermatomyositis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 34. North America Dermatomyositis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 35. North America Dermatomyositis Drug Sales Market Share by Country in 2019
Figure 36. North America Dermatomyositis Drug Revenue Market Share by Country in 2019
Figure 37. U.S. Dermatomyositis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 38. U.S. Dermatomyositis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. Canada Dermatomyositis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 40. Canada Dermatomyositis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 41. North America Dermatomyositis Drug Market Share by Type in 2019
Figure 42. North America Dermatomyositis Drug Market Share by Application in 2019
Figure 43. Europe Dermatomyositis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 44. Europe Dermatomyositis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 45. Europe Dermatomyositis Drug Sales Market Share by Country in 2019
Figure 46. Europe Dermatomyositis Drug Revenue Market Share by Country in 2019
Figure 47. Germany Dermatomyositis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 48. Germany Dermatomyositis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. France Dermatomyositis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 50. France Dermatomyositis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. U.K. Dermatomyositis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 52. U.K. Dermatomyositis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Italy Dermatomyositis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. Italy Dermatomyositis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Russia Dermatomyositis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 56. Russia Dermatomyositis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Europe Dermatomyositis Drug Market Share by Type in 2019
Figure 58. Europe Dermatomyositis Drug Market Share by Application in 2019
Figure 59. Asia Pacific Dermatomyositis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 60. Asia Pacific Dermatomyositis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 61. Asia Pacific Dermatomyositis Drug Sales Market Share by Region in 2019
Figure 62. Asia Pacific Dermatomyositis Drug Revenue Market Share by Region in 2019
Figure 63. China Dermatomyositis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 64. China Dermatomyositis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. Japan Dermatomyositis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 66. Japan Dermatomyositis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. South Korea Dermatomyositis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. South Korea Dermatomyositis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. India Dermatomyositis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. India Dermatomyositis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Australia Dermatomyositis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. Australia Dermatomyositis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Taiwan Dermatomyositis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. Taiwan Dermatomyositis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Indonesia Dermatomyositis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Indonesia Dermatomyositis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Thailand Dermatomyositis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Thailand Dermatomyositis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Malaysia Dermatomyositis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Malaysia Dermatomyositis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Philippines Dermatomyositis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Philippines Dermatomyositis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Vietnam Dermatomyositis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 84. Vietnam Dermatomyositis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Asia Pacific Dermatomyositis Drug Market Share by Type in 2019
Figure 86. Asia Pacific Dermatomyositis Drug Market Share by Application in 2019
Figure 87. Latin America Dermatomyositis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 88. Latin America Dermatomyositis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 89. Latin America Dermatomyositis Drug Sales Market Share by Country in 2019
Figure 90. Latin America Dermatomyositis Drug Revenue Market Share by Country in 2019
Figure 91. Mexico Dermatomyositis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 92. Mexico Dermatomyositis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Brazil Dermatomyositis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 94. Brazil Dermatomyositis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Argentina Dermatomyositis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 96. Argentina Dermatomyositis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Latin America Dermatomyositis Drug Market Share by Type in 2019
Figure 98. Latin America Dermatomyositis Drug Market Share by Application in 2019
Figure 99. Middle East and Africa Dermatomyositis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 100. Middle East and Africa Dermatomyositis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 101. Middle East and Africa Dermatomyositis Drug Sales Market Share by Country in 2019
Figure 102. Middle East and Africa Dermatomyositis Drug Revenue Market Share by Country in 2019
Figure 103. Turkey Dermatomyositis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 104. Turkey Dermatomyositis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Saudi Arabia Dermatomyositis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 106. Saudi Arabia Dermatomyositis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. U.A.E Dermatomyositis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 108. U.A.E Dermatomyositis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 109. Middle East and Africa Dermatomyositis Drug Market Share by Type in 2019
Figure 110. Middle East and Africa Dermatomyositis Drug Market Share by Application in 2019
Figure 111. North America Dermatomyositis Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 112. North America Dermatomyositis Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Europe Dermatomyositis Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 114. Europe Dermatomyositis Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Asia Pacific Dermatomyositis Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 116. Asia Pacific Dermatomyositis Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Latin America Dermatomyositis Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 118. Latin America Dermatomyositis Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Middle East and Africa Dermatomyositis Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 120. Middle East and Africa Dermatomyositis Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Porter's Five Forces Analysis
Figure 122. Channels of Distribution
Figure 123. Distributors Profiles
Figure 124. Bottom-up and Top-down Approaches for This Report
Figure 125. Data Triangulation
Figure 126. Key Executives Interviewed
小売薬の世界市場（～2026年） A drug is any substance (other than food that provides nutritional support) that, when inhaled, injected, smoked, consumed, absorbed via a patch on the skin, or dissolved under the tongue causes a temporary physiological (and often psychological) change in the body. Increasing industry share of Asia…- 糖尿病性神経障害治療薬の世界市場（～2026年） A drug used to treat mental illness caused by diabetes Market Analysis and Insights: Global Diabetic Neurological Disorder Therapeutic Drug Market The global Diabetic Neurological Disorder Therapeutic Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CA…
- ANCA関連血管炎薬の世界市場（～2026年） Market Analysis and Insights: Global Anca Vasculitis Drug Market The global Anca Vasculitis Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Anca Vasculitis Drug Scope and Market Size Anca Vasculitis Drug market is…
- 甲状腺未分化癌治療薬の世界市場（～2026年） Market Analysis and Insights: Global Anaplastic Thyroid Cancer Drug Market The global Anaplastic Thyroid Cancer Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Anaplastic Thyroid Cancer Drug Scope and Market Size …
- 大麻薬の世界市場（～2026年） Drugs with chemicals taken directly from the marijuana plant，or with synthetic versions of chemicals naturally found in marijuana. Market Analysis and Insights: Global Cannabis Drug Market The global Cannabis Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020,…